Arcellx has entered into a definitive agreement to be acquired by Gilead Sciences for $115.00 per share in cash and one contingent value right of $5.00 per share upon achieving specified clinical and regulatory milestones. The transaction implies an enterprise value of approximately $7.8 billion and remains subject to customary regulatory approvals and shareholder consent.

Halper Sadeh LLC has launched an investigation into whether the board and Gilead Sciences breached fiduciary duties or violated federal securities laws by negotiating deal terms that could restrict superior competing offers and inadequately inform shareholders of material deal provisions. The firm is evaluating potential claims to secure additional consideration and disclosures.

Pending the outcome of the investigation, shareholders could benefit from enhanced deal terms, including potential price increases or additional milestone payments. Any successful legal action might extend the merger timetable and encourage rival bids, potentially driving up the final acquisition price.